ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harald C. Eichstaedt
Charles D. Fraser, Jr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ündar, A.
Right arrow Articles by Fraser, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ündar, A.
Right arrow Articles by Fraser, C. D., Jr
Related Collections
Right arrow Extracorporeal circulation

Ann Thorac Surg 2002;74:355-362
© 2002 The Society of Thoracic Surgeons

Original article: cardiovascular

Novel anti-factor D monoclonal antibody inhibits complement and leukocyte activation in a baboon model of cardiopulmonary bypass

Akif Ündar, PhD*a,b,c, Harald C. Eichstaedt, MDc, Fred J. Clubb, Jr, DVM, PhDc, Michael Fung, PhDd, Meisheng Lu, MDd, Joyce E. Bigley, CCPc, William K. Vaughn, PhDe, Charles D. Fraser, Jr, MDa,c,f

a Congenital Heart Surgery Service, Texas Children’s Hospital, Houston, Texas, USA
b Division of Congenital Heart Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
c Cullen Cardiovascular Surgical Research Laboratories, Texas Heart Institute, Houston, Texas, USA
d Tanox, Inc., Texas Heart Institute, Houston, Texas, USA
e Department of Biostatistics and Epidemiology, Texas Heart InstituteHouston, Texas, USA
f Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA

* Address reprint requests to Dr Ündar, Texas Children’s Hospital/Baylor College of Medicine, Congenital Heart Surgery Service, 6621 Fannin Street, Mail Code WT 19345-H, Houston, TX 77030-2399 USA
e-mail: aundar{at}bcm.tmc.edu

Presented at the Poster Session of the Thirty-eighth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2002.


   Abstract
Top
 Footnotes
 Abstract
Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Background. Adverse outcomes after cardiopulmonary bypass (CPB) are often related to systemic inflammation triggered by complement and leukocyte activation. To determine how inhibition of the alternative complement pathway affects systemic inflammation and tissue injury, we studied a novel monoclonal antibody (Mab), anti-human factor D murine Mab 166-32, in baboons.

Methods. Fourteen baboons (mean weight, 15 kg) underwent hypothermic CPB. The treatment group (n = 7) received a single injection of anti-factor D Mab 166–32 (5 mg/kg), and the control group (n = 7) was given saline solution. After initiation of CPB, all animals were subjected to 20 minutes of core cooling (rectal temperature, 27°C), followed by 60 minutes of aortic cross-clamping, 25 minutes of rewarming, and 30 minutes of normothermic CPB. Blood samples were collected before CPB, during CPB, and 1, 2, 3, 6, and 18 hours after CPB. To measure neutrophil and monocyte activation, we performed flow cytometry for CD11b expression, ELISA for complement activation (Bb, C3a, C4d, and sC5b-9) and interleukin-6 (IL-6) production, and tissue injury studies for creatine kinase MB isoenzymes (CK-MB), creatine kinase (CK), and lactic dehydrogenase (LDH) levels.

Results. Anti-factor D Mab almost completely inhibited plasma Bb, C3a, and sC5b-9 production during CPB (P < .001). CD11b expression on neutrophils (129 ± 5% vs. 210 ± 42%; P = .0006) and on monocytes (139 ± 14% vs. 245 ± 43%; P = .0002) was also lower in the treatment group during CPB. The treated animals had a significantly smaller increase in plasma IL-6 concentrations than did the control animals (71 ± 27 pg/mL vs. 104 ± 54 pg/mL; P = .0002). CK-MB levels were also lower in the treatment group 6 hours after the end of CPB (204 ± 30 vs. 335 ± 59 IU/L; P = .003) and 18 hours after the end of CPB (P < .05). Creatine kinase levels (6 and 18 hours after the end of CPB) and LDH levels (3 and 6 hours after the end of CPB) showed patterns similar to those of CK-MB (P < .05).

Conclusions. The alternative complement pathway plays a major role in systemic inflammation during CPB. Inhibition of complement activation via the alternative pathway by anti-factor D Mab 166–32 significantly reduces leukocyte activation and tissue injury in our baboon model.


   Introduction
Top
 Footnotes
 Abstract
 Introduction
Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Accumulating evidence indicates that cardiac surgery induces systemic inflammatory responses, particularly when cardiopulmonary bypass (CPB) is used [1–5]. CPB induces complex inflammatory responses characterized by the activation of complement, leukocytes, platelets, and cytokine production. These systemic responses are attributed to several factors, including exposure of blood to nonphysiologic surfaces of the heart-lung circuit, ischemia-reperfusion of the involved tissues, surgical trauma and hypothermia [6–8]. Systemic inflammation causes many postoperative complications, including vital organ dysfunction that can lead to multiorgan failure and even death [2, 6–10]. It also results in prolonged hospitalization and increased hospital costs. The intensity of the inflammatory response appears to be directly correlated with the severity of CPB-related morbidity. Currently, there is no effective method for preventing this systemic inflammatory response syndrome in cardiac surgery patients, although some have attempted to ameliorate this with heparin-bonded circuits, leukocyte filters, or modified ultrafiltration.

The complement cascade is activated by 3 different pathways: the alternative, classical [11], and lectin [12] pathways. The alternative pathway plays a major role in complement activation because it amplifies the classical and lectin pathways [12–14]. Therefore, inhibition of the alternative complement pathway may help minimize complement activation during CPB more than would inhibition of the classical or lectin pathways. Factor D is an ideal target for inhibiting the alternative complement pathway because factor D is a rate-limiting enzyme that is essential for activation and amplification of the alternative complement pathway. Compared with other soluble complement components, factor D has an extremely low concentration in the blood (about 2 µg/mL) [11].

Previously, we clearly documented that anti-factor D monoclonal antibody (Mab) 166-32 significantly inhibits the alternative complement pathway, including the production of Bb, C3a, sC5b-9, and C5a, and upregulation of CD11b on neutrophils and of CD62P on platelets; the release of neutrophil-specific elastase and myeloperoxidase; the production of pro-inflammatory cytokine interleukin (IL)-8; and the release of thrombospondin from platelets in a simulated CPB circuit using human blood [15]. The purpose of the present study was to investigate the effects of a novel Mab, anti-factor D Mab 166-32, on complement and leukocyte activation and tissue injury in a baboon model during and after CPB. We hypothesized that anti-factor D would inhibit complement and leukocyte activation and, therefore, reduce tissue injury.


   Material and methods
Top
 Footnotes
 Abstract
 Introduction
 Material and methods
Results
 Comment
 Acknowledgments
 References
 
Fourteen healthy adult baboons (mean body weight, about 15 kg) were used in the study. All the animals received humane care according to the "Guide for the Care and Use of Laboratory Animals" of the National Research Council (National Academy Press, revised 1996). The baboons were pre-screened for negative serological reactivity with Mab 166-32 by ELISA.

Anesthesia and surgery
Upon transfer from a squeeze cage to preoperative holding area, each baboon was sedated with an intramuscular injection of 10 mg/kg of ketamine hydrochloride. A 20 gauge angiocatheter was placed in the cephalic vein, and 5.0 mg of diazepam were administered intravenously. The oral and nasal airways were masked with 1.5% to 3.0% isoflurane for anesthesia induction. Intubation was achieved with a size 6 endotracheal tube. Anesthesia was maintained with 0.80% to 2.25% isoflurane, 100% O2, and an inspiratory tidal volume of 13 mL/kg at a rate of 13 breaths per minute throughout the surgical procedure except during CPB. Pancuronium bromide (Pavulon), 0.1 mg/kg, was administered to achieve adequate muscle paralysis.

Carotid artery and internal jugular vein were exposed for continuous arterial pressure monitoring and recording and volume administration/antibody injection, respectively. After a median sternotomy, the pericardium was opened, and the ascending aorta and the right atrium were cannulated with a 14-French aortic cannula (Argyle, St. Louis, MO) and a 24 or 28-French single-stage venous cannula (Polystan A/S, Varlose, Denmark), respectively. Heparin (300 units/kg) was administered for anti-coagulation. The CPB circuit included a conventional non-pulsatile roller pump (Stöckert, Irvine, CA, USA), hollow-fiber membrane oxygenator (Capiox SX10; Terumo Corp., Tokyo, Japan), arterial filter (Terumo), and pediatric tubing set (Baxter/Bentley, Irvine, CA). Lactated Ringer’s solution was then used to prime the extracorporeal circuit. The priming volume for the whole circuit was approximately 600 ml. This low-prime circuit was used to avoid the need of donor blood. During CPB, the hematocrit was maintained at 24% to 26%. The pump flow rate was maintained at 100 ml/kg/min. During CPB, the mean arterial pressure was maintained at 50 - 60 mm Hg by adding isoflurane through the oxygenator as an inflow conduit. At the beginning of hypothermic CPB, a total dose of 200 cc of crystalloid cardioplegia (modofied Kirklin solution) was administered into the aortic root via a Conducer blood cardioplegia circuit (Terumo/Sarns, Somerset, NJ) for 5 minutes. At the end of CPB, protamine (1 mg/100 units of heparin) was administered for heparin neutralization. The heart rate and systemic arterial pressure were continuously monitored. At the end of the experiment, each animal was euthanized with an intravenous bolus of Beuthanasia-D (0.22 mg/kg).

Experimental design and blood sampling
Of the 14 baboons, 7 animals (the treatment group) received a single injection of anti-factor D Mab 166-32 (5 mg/kg) (Tanox, Inc., Houston, TX), and the other 7 animals (the control group) were given saline solution. We chose this dosage of Mab 166-32 because we estimated that it would be sufficient to completely neutralize the factor D for about 7 hours, based on data from a separate study in which Mab 166-32 (1 mg/kg) completely inhibited factor D in rhesus monkeys for at least 1.5 hours. Mab 166-32 was found to inhibit baboon and monkey factor D as well as it inhibited human factor D.

After initiation of CPB, all animals were subjected to 20 minutes of core cooling (rectal temperature, 27°C), followed by 60 minutes of aortic cross-clamping, 25 minutes of rewarming, and 30 minutes of normothermic CPB. Eight of the experiments (4 in each group) were terminated 6 hours after the end of CPB; the remaining 6 experiments (3 in each group) were terminated 18 hours after the end of CPB.

Blood samples were taken from the animals for assays at different time points: Before injection of Mab 166-32 or saline (at 0 hour), after injection of Mab 166-32 or saline (at 45 minutes), before CPB (at 1 hour), 10 minutes in CPB at 37°C, 25 minutes in CPB at 27°C, 85 minutes in CPB at 27°C, 105 minutes in CPB at 37°C after re-warming, 135 minutes in CPB at 37°C prior to protamine administration (at 3.25 hours), 30 minutes off CPB at 37°C, 1 hour off CPB at 37°C, 2 hours off CPB at 37°C, 6 hours off CPB at 37°C (at 9.25 hours), and finally 18 hours off CPB at 37°C (at 21.25 hours).

Plasma and whole blood samples were used in different assays based on the procedures described earlier [15]:

  1. Plasma concentration of free Mab 166-32 was measured by ELISA using factor D as coating antigen.
  2. Functional activity of factor D in plasma was measured by two hemolytic assays: rabbit red blood cells for the alternative complement pathway and sensitized chicken red blood cells for the classical complement pathway.
  3. Plasma concentrations of complement Bb, C4d, and C3a were measured by ELISA (Quidel Corp., San Diego, CA), and sC5b-9 by ELISA [16].
  4. Expression of CD11b on neutrophils and monocytes was measured by immunofluorocytometric methods.
  5. Plasma concentrations of IL-6 was measured by ELISA (BioSource International, Inc., Camarillo, CA).
  6. Plasma concentration of lactic dehydrogenase (LDH), creatine kinase (CK), creatine kinase MB isoenzymes (CK-MB), creatinine, and blood urea nitrogen (BUN) were measured by standard blood chemistry assays.

Statistical analysis
Two-sided ANOVA with repeated measures was used for statistical analysis between control and antibody groups. Pre-planned comparisons between control and treated groups within each experimental stage were tested using contrasts. No correction for multiple comparisons were made. A p value less than 0.05 was considered statistically significant. All results were expressed as mean ± standard error of mean (SEM).


   Results
Top
 Footnotes
 Abstract
 Introduction
 Material and methods
 Results
Comment
 Acknowledgments
 References
 
Pharmacokinetics of Mab 166-32
The plasma concentrations of the free antibody were measured by ELISA using human factor D as coating antigen (Fig 1). At 45 minutes after the antibody injection, the plasma concentration of free Mab 166-32 was 68.3 ± 9.9 µg/ml. The antibody concentration then decreased to 23.4 ± 4.4 µg/ml at 10 minutes after CPB, as a result of hemodilution upon the initiation of CPB. The antibody concentration remained at 10–13 µg/ml until 3 hours after CPB. The antibody concentration was reduced to 6.2 ± 2.3 µg/ml at 6 hours after CPB and to 1.7 ± 3.9 µg/ml at 18 hours after CPB.



View larger version (19K):
[in this window]
[in a new window]
  		Fig 1. Plasma concentration of free Mab 166-32 by ELISA using factor D as coating antigen (n = 7, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 
Using an alternative complement hemolytic assay with rabbit red blood cells, the functional activity of factor D in the plasma samples from the Mab 166-32 treated animals was measured (Fig 2). The alternative complement hemolytic activity of the baboon plasma samples was completely inhibited at 6 hours after CPB. At 18 hours after CPB, the inhibition was reduced to 79.3 ± 10%. The data are consistent with the presence of free Mab 166-32 in the circulation until 18 hours after CPB (Fig 1). In hemolytic assays using sensitized chicken red blood cells to measure the classical complement activity, the corresponding plasma samples from the Mab 166-32 treated animals did not show any reduction in the classical complement activity by the antibody (Fig 2). These results confirm that Mab 166-32 is a specific inhibitor of the alternative complement pathway.



View larger version (22K):
[in this window]
[in a new window]
  		Fig 2. Functional activity of factor D in baboon plasma by two hemolytic assays: rabbit red blood cells for the alternative complement pathway and sensitized chicken red blood cells for the classical complement pathway (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 
Activation of complement, leukocytes and IL-6
The specificity of Mab 166-32 in inhibiting the alternative complement pathway was also demonstrated by the complete inhibition of Bb formation (Fig 3A). Bb is the activation product of factor B upon proteolytic cleavage by factor D. The increase in Bb formation in the control animals is attributed to the activation of the alternative complement pathway during CPB. The reduction of plasma Bb concentration below the baseline in the Mab 166-32 treated animals could be due to the inhibition of the physiological activation of the alternative complement pathway.



View larger version (22K):
[in this window]
[in a new window]
  		Fig 3. (A) Plasma Bb production (n = 7 in each group, mean ± SEM). (B) Plasma C4d production (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 
Activation of the classical complement pathway was determined by measuring C4d, which is a specific marker for the activation of C4 in the classical complement pathway. In the study, the plasma levels of C4d in both the Mab 166-32 treated and control animals were relatively stable with reference to the baseline (Fig 3B). However, there was a significant increase of C4d in both animal groups after neutralization of heparin with protamine at the end of the CPB as compared with the baseline, indicating the activation of the classical pathway as reported earlier in other studies [13–15, 17].

There was a dramatic increase of plasma C3a levels in the control animals (Fig 4A). In contrast, animals treated with Mab 166-32 showed almost complete inhibition of C3a production. A slight increase of C3a level is observed in the Mab 166-32 treated animals after neutralization of heparin with protamine. Anti-factor D Mab significantly inhibited sC5b-9 production (Fig 4B). Together, the results from Figs 3 and 4 support the notion that complement activation during CPB is predominantly mediated by the alternative complement pathway.



View larger version (25K):
[in this window]
[in a new window]
  		Fig 4. (A) Plasma C3a production (n = 7 in each group, mean ± SEM). (B) Plasma sC5b-9 production (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 
Activation of neutrophils and monocytes in the baboons was examined by measuring CD11b ({alpha}-integrin) expression using immunofluorocytometric methods. In the control animals, CD11b expression on neutrophils increased rapidly and reached maximum at about 85 minutes after the start of CPB (209 ± 42.9% of the baseline) (Fig 5). It then declined slowly back to around the baseline. In contrast, the increase of CD11b expression on neutrophils in the Mab 166-32 treated animals ws much delayed and smaller in magnitude (Fig 5). The maximum level of CD11b expression was 129.3% ± 5.5% of the baseline in the antibody group. Similarly, the upregulation of CD11b expression on monocytes in Mab 166-32 treated animals was also reduced as compared to the control animals (Fig 6).



View larger version (23K):
[in this window]
[in a new window]
  		Fig 5. CD11b expression on neutrophils (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 


View larger version (23K):
[in this window]
[in a new window]
  		Fig 6. CD11b expression on monocytes (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 
The effect of Mab 166-32 treatment on pro-inflammatory cytokine IL-6 was also examined. Baboons treated with Mab 166-32 had a significantly smaller increase in plasma IL-6 concentration as compared to the control animals (Fig 7).



View larger version (18K):
[in this window]
[in a new window]
  		Fig 7. Plasma interleukin 6 (IL-6) levels (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass; Inj = injection of.)

 
The effects of Mab 166-32 treatment on tissue injury were also studied. Specifically for myocardial injury, the increase of plasma CK-MB levels at 6 and 18 hours after CPB was significantly lower in the Mab 166-32 treated animals as compared to the control animals (Fig 8). Similarly, the plasma CK levels were lower in the Mab 166-32 treated animals as compared to the control animals at 6 hours (299% ± 47% vs. 470% ± 101% P = 0.01) and 18 hours after CPB (420% ± 70% vs. 762% ± 358%, P = 0.0004). The increase of plasma LDH levels was also significantly lower in the Mab 166-32 treated animals as compared to the control animals at 3 hours (120% ± 80% vs. 186% ± 17, P = 0.0002) and 6 hours after CPB (161% ± 51% vs. 202% ± 46%, P = 0.03). No plasma samples for the LDH measurement were collected at 18 hours after CPB.



View larger version (19K):
[in this window]
[in a new window]
  		Fig 8. Plasma creatinine kinase isozymes (CK-MB) levels (n = 7 in each group, mean ± SEM). (CPB = cardiopulmonary bypass.)

 
Eighteen hours after CPB, we also examined the renal function of the baboons. A significant reduction in the increase of normalized plasma creatinine levels was found in the treated baboons as compared to the control animals (116 ± 13% vs. 141 ± 15%; P = .01). However, the absolute numbers (1.1 ± 0.2 mg/dL) were identical in both groups. Throughout the experiments, there was no significant intergroup difference in the BUN levels.


   Comment
Top
 Footnotes
 Abstract
 Introduction
 Material and methods
 Results
 Comment
Acknowledgments
 References
 
The triggering mechanism of systemic inflammatory syndrome in CPB is associated with complement activation [3, 7, 13, 17–19], although contact activation is also involved [18–20]. This activation leads to multiple humoral and cellular inflammatory responses.

The complement cascade can be activated directly by either the alternative or the classical pathway [11], and indirectly by the lectin pathway [12]. In the alternative pathway, C3 is activated by exposure of blood to the artificial surfaces of the CPB circuit or by contact of C3 with complex polysaccharides and endotoxin. In the classical pathway, C1 is activated usually by antibody-antigen complexes. The classical pathway can also be activated by the administration of protamine to neutralize heparin immediately after weaning from CPB [13, 17].

Contact activation causes activation of factor XII, which is involved in the generation of plasmin [18–20]. Plasmin can activate C1 and C3. Complement activation generates a number of active split products, including the anaphylatoxins C3a and C5a. In turn, these substances stimulate the release of histamine, proteases and leukotrienes from mast cells and basophils, resulting in enhanced vascular permeability, vasoconstriction, and tissue inflammation [18, 20]. In addition, C3a and C5a are potent stimulators of neutrophils and monocytes, respectively [1, 21, 22]. The activation of these cells can result in platelet-leukocyte aggregation and release of cytotoxic substances from neutrophils, such as oxidative free radical and proteases.

During CPB, the alternative complement pathway is found to be the major mechanism of complement activation [12–15]. In a prospective clinical study, cardiac, pulmonary, and renal dysfunction was significantly related to heightened C3a levels in the blood after CPB [2]. Both C5a and C5b-9 activate endothelial cells to express adhesion molecules essential for sequestration of activated leukocytes which then mediate tissue inflammation and injury [23, 24]. In our baboon model, we have demonstrated that the alternative complement pathway is the major mechanism of complement activation, and anti-factor D Mab significantly inhibited Bb, C3a, and sC5b-9 production.

During CPB, neutrophil activation can be triggered by a number of mediators, including C3a and C5a [1, 21, 22]. Neutrophil adherence to endothelial cells is the first step of tissue injury. Neutrophil-adhesive glycoprotein CD11b is primarily responsible for endothelial binding [25]. Neutrophil-endothelial adhesion is a major event leading to inflammation and reperfusion injury. Several studies have shown that CD11b expression levels on neutrophils are significantly increased after clinical or experimental cardiac surgery [1, 24, 25]. CD11b has also been shown to mediate lung injury and myocardial ischemia-reperfusion injury [23–25]. In our baboon model, the CD11b upregulation on neutrophils and monocytes was inhibited in the antibody treatment group as compared to the control group. The results are consistent with the fact that the CK, CK-MB, and LDH levels were significantly lower in the antibody treatment group after CPB. Collectively, anti-factor D Mab 166-32 was shown to reduce tissue injury due caused by systemic inflammation.

Interleukin-6 is produced by monocytes, macrophages, endothelial cells, and smooth muscle cells in response to their stimulation by TNF{alpha}, endotoxin, and particularly IL-1 [26, 27]. IL-6 is responsible for the generalized systemic inflammatory reaction known as the acute-phase response [26]. This reaction includes tachycardia and leukocytosis, as well as decreased synthesis of albumin and increased production of acute-phase proteins by hepatocytes. There is a significant correlation between the plasma levels of IL-6 and tissue injury [26–29]. In our baboon model, the increase of plasma IL-6 concentrations was reduced in the antibody treatment group as compared to the control group.

The data from our extracorporeal circulation study and the baboon study clearly demonstrate that the alternative complement pathway plays a predominant role in the inflammation and tissue injury in CPB [15]. Therefore specific inhibition of the alternative complement pathway instead of complete inhibition of all the complement pathways could be adequate and desirable. We anticipate that CPB patients will be treated with the anti-factor D Mab for a short duration (24–36 hours) during and immediately after the surgery. Factor D has a fast turnover rate in human (about 60% per hour). Therefore, once an appropriate dose of the antibody is used up in the neutralization of factor D, the alternative complement activity will resume quickly in 1–2 hours. Furthermore, a recent report by Biesma and associates have clearly shown that increased susceptibility for infections in individuals with partial factor D deficiency is unlikely [30].

Baboons were chosen as the animal model because Mab 166-32 does not react with factor D from non-primate animals (such as dogs and pigs) that might otherwise have been considered for this study. Himamatsu and associates have already shown that baboon blood has high immunologic cross-reactivity with most assays for human plasma proteins and cellular elements [31]. Clinical parameters of baboons compared favorably with normal clinical values established for humans [32].

Conclusions
Anti-factor D Mab 166-32 inhibits activation of the alternative complement pathway in a baboon model of CPB, thereby reducing the activation of neutrophils and monocytes, as well as the production of IL-6. Treatment with Mab 166-32 confers protection against myocardial injury. The alternative complement pathway may play a predominant role in the inflammation and tissue injury caused by extracorporeal circulation, surgical trauma, and ischemia/reperfusion. Therefore, Mab 166-32 could be useful for the treatment of systemic inflammatory response syndromes in CPB.


   Acknowledgments
Top
 Footnotes
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
References
 
This study was supported by grants from the National Institutes of Health, National Heart, Lung, and Blood Institute (Grant # HL65061), Bethesda, Maryland, and from Tanox, Inc., Houston, Texas. The authors thank Blake A. Deady and Aimee Porter for their excellent technical assistance and Virginia Fairchild for editorial assistance. Special thanks go to Professor Tom Eirik Mollnes, of the Department of Immunology and Transfusion Medicine of the University of Tromsø in Norway, for providing us reagents for sC5b-9 ELISA.


   Footnotes
Top
 Footnotes
Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 
Doctors Fung and Lu disclose that they have a financial relationship with Tanox, Inc.


   References
Top
 Footnotes
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 Acknowledgments
 References
 

  1. Chenoweth D.E., Cooper S.W., Hugli T.E. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Eng J Med 1981;394:497-503.
  2. Kirklin J.K., Westaby S., Blackstone E.H., Kirklin J.W., Chenoweth D.E., Pacifico A.D. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-857.[Abstract]
  3. Fosse E., Mollnes T.E., Ingvalden B. Complement activation during major operations with or without cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987;93:860-866.[Abstract]
  4. Steinberg J.B., Kapelanski D.P., Olson J.D. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008-1016.[Abstract]
  5. Asimakopoulos G. Mechanisms of the systemic inflammatory response. Perfusion 1999;14:269-277.[Free Full Text]
  6. Westaby S. Organ dysfunction after cardiopulmonary bypass: a systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987;13:89-95.[Medline]
  7. Schlag G., Redl H., Hallstrom S. The cell in shock: The origin of multiple organ failure. Resuscitation 1991;21:137-180.[Medline]
  8. Utley J.R. Pathophysiology of cardiopulmonary bypass: current issues. J Card Surg 1990;5:177-189.[Medline]
  9. Seghaye M.C., Duchateau J., Grabitz R.G. Complement activation during cardiopulmonary bypass in infants and children: relation to post-operative multiple system organ failure. J Thorac Cardiovasc Surg 1993;106:978-987.[Abstract]
  10. Moore F.D., Jr, Warner Kg., Assousa S. The effects of complement activation during cardiopulmonary bypass: attenuation by hypothermia, heparin, and hemodilution. Ann Surg 1988;8:95-103.
  11. Holers V.M. Complement. In: Rich R.R., ed. Clinical Immunology: Principles and Practice (2nd ed.). London: Mosby, 2001:21.1-21.18.
  12. Suankratay C., Zhang X.-H., Zhang Y., Lint T.F., Gewurz H. Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. J Immunol 1998;160:3006-3013.[Abstract/Free Full Text]
  13. Carr J.A., Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino) 1999;40:659-666.[Medline]
  14. Farries T.C., Steuer K.I.K., Atkinson J.P. The mechanism of activation of the alternative pathway of complement by cell-bound C4d. Mol Immunol 1990;27:1155-1161.[Medline]
  15. Fung M., Loubser P.G., Ündar A., et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 2001;122:113-122.[Abstract/Free Full Text]
  16. Mollnes T.E. Analysis of in vivo complement activation. In: Herzenberg L.A., Weir D.M., Herzenberg L.A., Blackwell C., eds. Weir’s Handbook of Experimental Immunology. Boston: Blackwell Science, 1997:78.1-78.8.
  17. Kirklin J.K., Chenoweth D.E., Naftel D.C., et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and hemodynamic state. Ann Thorac Surg 1986;41:193-199.[Abstract]
  18. Edmunds L.H., Jr Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998;66:S12-S16.[Abstract/Free Full Text]
  19. Mollnes T.E. Complement and biocompatibility. Vox Sang 1998;74 Supp 2:303-307.
  20. Levy J.H. Complement and contact activation. In: Levy J.H., ed. Anaphylactic Reactions in Anesthesia and Intensive Care. Boston: Butterworth-Heinemann, 1992:51-62.
  21. Haeffner-Cavaillon N., Cavaillon J.M., Laude M. C3a induces production and release of interleukin 1 by cultured human monocytes. J Immunol 1987;139:794-799.[Abstract]
  22. Cavaillon J.M., Fitting C., Haeffner-Cavaillon N. Recombinat C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990;20:253-257.[Medline]
  23. Gillinov A.M., Redmond J.M., Zehr K.J. Inhibition of neutrophil adhesion during CPB. Ann Thorac Surgery 1994;57:126-133.[Abstract]
  24. Wilson I., Gillinov A.M., Curtis W.E. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation 1993;88:372-379.[Abstract/Free Full Text]
  25. Carlos T.M., Harlan J.M. Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 1990;114:5-28.[Medline]
  26. Wang G.G., Clark S.C. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988;9:137-139.[Medline]
  27. Loppnow H., Libby P. Proliferating or Interleukin-1 activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990;85:731-738.
  28. Cruickshank A.M., Fraser W.D., Burns H.J.G. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990;79:161-165.[Medline]
  29. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.[Free Full Text]
  30. Biesma D.H., Hannema A.J., Velzen-Blad V., et al. A family with complement factor D deficiency. J Clin Invest 2001;108:233-240.[Medline]
  31. Hiramatsu Y., Gikakis N., Gorman J.H., et al. A baboon model for hematologic studies of cardiopulmonary bypass. J Lab Clin Med 1997;130:412-420.[Medline]
  32. Hainsey B.M., Hubbard G.B., Leland M., Brasky K.M. Clinical parameters of the normal baboons and chimpanzees. Lab Anim Scien 1993;43:236-243.



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
K. J. Katschke Jr., S. Stawicki, J. Yin, M. Steffek, H. Xi, L. Sturgeon, P. E. Hass, K. M. Loyet, L. DeForge, Y. Wu, et al.
Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement
J. Biol. Chem., April 17, 2009; 284(16): 10473 - 10479.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. Salvesen, M. Fung, O. D. Saugstad, and T. E. Mollnes
Role of Complement and CD14 in Meconium-Induced Cytokine Formation
Pediatrics, March 1, 2008; 121(3): e496 - e505.
[Abstract] [Full Text] [PDF]

Home page
 Card Surg AdultHome page
J. W. Hammon
Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation
Card. Surg. Adult, January 1, 2008; 3(2008): 370 - 389.
[Full Text]

Home page
 PerfusionHome page
A. Undar, W R. Owens, M. C. McGarry, D. L Surprise, V. D Kilpack, M. W Mueller, E D. McKenzie, and C. D Fraser Jr
Comparison of hollow-fiber membrane oxygenators in terms of pressure drop of the membranes during normothermic and hypothermic cardiopulmonary bypass in neonates
Perfusion, May 1, 2005; 20(3): 135 - 138.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. T. Lappegard, J. Riesenfeld, O.-L. Brekke, G. Bergseth, J. D. Lambris, and T. E. Mollnes
Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production
Ann. Thorac. Surg., March 1, 2005; 79(3): 917 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, and T. E. Mollnes
Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition
Ann. Thorac. Surg., July 1, 2004; 78(1): 38 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes
Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation
Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Yoshimura, Y. Hiramatsu, Y. Sato, S. Homma, Y. Enomoto, T. Jikuya, and Y. Sakakibara
ONO-6818, a novel, potent neutrophil elastase inhibitor, reduces inflammatory mediators during simulated extracorporeal circulation
Ann. Thorac. Surg., October 1, 2003; 76(4): 1234 - 1239.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. C. Riedemann and P. A. Ward
Complement in Ischemia Reperfusion Injury
Am. J. Pathol., February 1, 2003; 162(2): 363 - 367.
[Full Text] [PDF]

Home page
 Card Surg AdultHome page
P. Menasche and L. H. Edmunds Jr.
Extracorporeal Circulation: The Inflammatory Response
Card. Surg. Adult, January 1, 2003; 2(2003): 349 - 360.
[Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Harald C. Eichstaedt
Charles D. Fraser, Jr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ündar, A.
Right arrow Articles by Fraser, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ündar, A.
Right arrow Articles by Fraser, C. D., Jr
Related Collections
Right arrow Extracorporeal circulation

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS